2024-512749-18-00招募中2 期
Isa-RVD Study: Phase II, Multi-centre, Single-Arm, Open-Label Study to evaluate the efficacy and safety of the combination regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 52
- 试验地点
- 8
- 主要终点
- VGPR or better rate at the end of two cycles of induction treatment, defined as the proportion of patients who have achieved VGPR or better, according IMWG criteria (Kumar et al. 2016), at the end of two cycles of induction treatment.
研究概览
简要总结
To evaluate the Very Good Partial Response (VGPR) or better rate at the end of two cycles of induction treatment, defined as the proportion of patients who have achieved VGPR or better, according to IMWG criteria (Kumar et al. 2016), at the end of two cycles of induction treatment.
研究设计
- 分配方式
- Not Applicable
- 主要目的
- Single-arm, Open-label
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Previously diagnosed with MM based on standard IMWG criteria and currently requires treatment.
- •Provided voluntary written informed consent before performance of any study-related procedures not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.
- •Age ≥18 years, ≤75 years, with patients over the age of 70 requiring CI approval.
- •Measurable disease defined as at least one of the following: • Serum M protein ≥0.5g/dL (≥5g/L) • Urine M protein ≥200 mg/24 hours • Serum FLC assay: Involved FLC assay ≥10 mg/dL (≥100 mg/L) and an abnormal serum FLC ratio (<0.26 or >1.65).
- •Screening laboratory evaluations within the following parameters: • ANC ≥ 1,000 cells/dL (1.0 x 109/L) (growth factors cannot be used within 14 days before first study treatment administration) • Platelet count ≥75,000 cells/dL (75 x 109/L) if <50% BM nucleated cells are plasma cells, ≥30,000 cells/dL (30 x 109/L) if ≥50% of BM nucleated cells are plasma cells (without transfusions required during the 3 days prior to the screening haematologic test) • Total bilirubin ≤2.0 X ULN (except patients with Gilbert Syndrome, who are eligible if total bilirubin <3.0 mg/dL) • AST (SGOT) and ALT (SGPT) ≤3.0 x ULN • Haemoglobin ≥8g/dL • Calculated CrCl ≥30 mL/min.
- •ECOG performance status ≤
- •Participant agrees to be registered into the mandatory Risk Management Programme for Lenalidomide and be willing and able to comply with the requirements of this programme.
- •Ability to understand and the willingness to sign a written informed consent document.
- •Participant is considered eligible for ASCT by the treating physician.
排除标准
- •Prior therapy for multiple myeloma. Participants who received smouldering treatment qualify to participate as long as the prior treatment was not a CD38 therapy.
- •POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes).
- •Known active infection requiring parenteral or oral anti-infective treatment within 7 days of start of study treatment.
- •Active hepatitis B or hepatitis C viral infection.
- •Pregnant or breastfeeding female or female who intends to become pregnant during the participation in the study. FCBP unwilling to prevent pregnancy by the use of a highly effective method of contraception for ≥4 weeks before the start of study treatment, during treatment (including dose interruptions) and up to 5 months following the last dose of study treatment and/or who are unwilling or unable to be tested for pregnancy before study treatment initiation (2 negative tests) and then monthly up to 5 months following the last dose of study treatment.
- •Male participants who disagree to practice true abstinence or disagree to use highly effective contraception during sexual contact with a pregnant female or FCBP while participating in the study during dose interruptions and at least 3 months following study treatment discontinuation, even if he has undergone a successful vasectomy.
- •Receiving any other investigational agents.
- •Hypersensitivity to steroids, or H2 blockers that would prohibit further treatment with these agents.
- •Inability to tolerate thromboprophylaxis.
- •Hypersensitivity (or contraindication) to dexamethasone, sucrose histidine (as base and hydrochloride salt), boron, mannitol, and polysorbate 80, or to any of the components of the study therapy.
- •Diagnosed or treated for another malignancy within 3 years prior to enrolment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in-situ malignancy, or low risk prostate cancer after curative therapy.
- •Central nervous system involvement.
- •Peripheral neuropathy ≥ Grade 3, or Grade 2 with pain on clinical examination during the screening period.
- •Any medical or psychiatric illness that, in the Investigator’s opinion, would impose excessive risk to the patient or would adversely affect his/her participating in this study.
- •Concurrent uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, Grade 3 thromboembolic event or myocardial infarction within 6 months prior to enrolment
- •Prior major surgical procedure or radiation therapy within 4 weeks of initiation of study treatment (this does not include limited course of radiation used for management of bone pain within 7 days of study treatment).
- •Daily requirement for corticosteroids (equivalent to >10 mg/day prednisone for more than 7 days (except for inhalation corticosteroids). Patients may receive corticosteroids for the management of their MM that should not exceed the equivalent of 160mg of dexamethasone in a 2-week period and should be stable for at least 7 days prior to the initiation of study treatment.
- •Concurrent symptomatic amyloidosis or plasma cell leukaemia.
结局指标
主要结局
VGPR or better rate at the end of two cycles of induction treatment, defined as the proportion of patients who have achieved VGPR or better, according IMWG criteria (Kumar et al. 2016), at the end of two cycles of induction treatment.
VGPR or better rate at the end of two cycles of induction treatment, defined as the proportion of patients who have achieved VGPR or better, according IMWG criteria (Kumar et al. 2016), at the end of two cycles of induction treatment.
次要结局
- CR and sCR rate after one year and two years of maintenance therapy.
- ORR and rate of VGPR or better following one year of maintenance therapy. ORR will be defined as achieving a partial response or better.
- Time to VGPR or better.
- Negative MRD rate following induction, ASCT and after 1 and 2 years of maintenance treatment.
- Clinical outcomes including: TTP, PFS, OS, DOR.
- Safety and tolerability of Isa-RVD.
- Stem cell yield after mobilization.
- CR and sCR rate following induction, ASCT and maintenance treatment in the subgroup of non-IgG kappa positive patients.
- Duration of and time to sCR and time to CR in the subgroup of non-IgG kappa positive patients.
- Clinical efficacy in high-risk cytogenetic subgroups: del(1p), gain of 1q, del(17p), t(4;14), t(14;16), t(14;20).
- Immune profiling (NK, T, and B cells) and T-cell receptor sequencing.
- MRD detection performed by flow cytometry and NGS.
- Immunogenicity of Isatuximab.
- PROs.
- Stem cell yield after mobilization (number of CD34+ cells)
研究者
Chief Operations Officer
Scientific
Cancer Trials Ireland
研究点 (8)
Loading locations...
相似试验
招募中
2 期
A phase II study assessing safety and efficacy of REPotrectinib in ROS1-positive non-small cell lung cancer patients with active brain mEtastasis (The REPOSE study)2023-508112-35-00Medica Scientia Innovation Research S.L., Medical University Of Vienna20
招募中
3 期
IFM2020-05-BENEFIT-Multicenter Open label Phase 3 study of Isatuximab plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly diagnosed Non-Frail transplant Ineligible Multiple Myeloma elderly patients (≥ 65; < 80 years).2024-517215-67-00Centre Hospitalier Universitaire De Poitiers270
招募中
2 期
Study that aims to investigate how effective and safe the use of a novel modified release tablet formulation of Colesevelam hydrochloride-MMX is for patients with idiopathic bile acid diarrhoea (BAD), randomly allocated to 2 different dose regimens of the active product or to the inactive placebo formulation.2024-511993-55-00Cosmo Technologies Limited120
进行中（未招募）
2 期
A MULTICENTER, SINGLE-ARM, THREE COHORT, PHASE II TRIAL OF PATRITUMAB DERUXTECAN (HER3-DXD) IN PATIENTS WITH ACTIVE BRAIN METASTASES FROM HER3-EXPRESSING ADVANCED BREAST CANCER AND NON–SMALL CELL LUNG CANCER, AND IN PATIENTS WITH LEPTOMENINGEAL CARCINOMATOSIS FROM HER3-EXPRESSING ADVANCED SOLID TUMORS (The TUXEDO-3 Study)2023-503251-10-00Medica Scientia Innovation Research S.L.60
招募中
3 期
A Randomized Clinical Trial, Multicentre, Open-label, Parallel-group, to define the best Strategy for the management of hEart failure aNd chronic kidney disease among elderly patients with or at high risk of hyperKalemia in spAin by optimizing the use of RAASi with SZC: SENEKA Study2024-513971-42-00Hospital Clinico Universitario De Valencia94